Oncomine NGS Solutions for Hemato-oncology Research

Unlocking more blood cancer insights with NGS

Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide1.

 

These challenging disorders are genetically complex, often harboring a range of somatic mutations. In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases.

hemato-oncology couple

Benefit of NGS for hemato-oncology research

Traditional molecular testing involves iterative single-analyte approaches, complex workflows, all of which results in variable, often lengthy, turnaround times.

 

Next-generation sequencing (NGS) has revolutionized the study of  hematologic malignancies by streamlining genetic profiling. NGS allows for efficient, simultaneous assessment of multiple genetic biomarkers with a single assay. Advancements in NGS automation enable results in as few as 1-2 days.

Video Player is loading.
Current Time 0:00
Duration 1:50
Loaded: 0.00%
Stream Type LIVE
Remaining Time 1:50
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Hemato-oncology research NGS solutions

    Deepen your understanding of hematological malignancies with an unmatched offering of NGS testing solutions and capabilities. We offer a range of NGS assays for applications across a spectrum of disease research areas. Each assay is provided as part of a complete solution on our trusted NGS platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.


    Integrated analysis software streamlines reporting and facilitates the interpretation of results. Unmatched workflow automation simplifies the testing process, enabling any laboratory to adopt NGS testing—including those without prior experience and expertise.

    Oncomine Myeloid Assays GX v2

    myeloid gx

    Oncomine Myeloid MRD Assays (RUO)

    Myeloid MRD Assays

    Oncomine Immune Repertoire Assays

    Immune Repertoire Assays

    Customer presentations

    Moving toward a brighter future in hemato-oncology 

    Our customers and collaborators are making incredible research advancements, disrupting traditional paradigms, and bringing forth new insights and approaches for understanding hematologic malignancies. Our NGS technology has been embraced by some of the top minds in the world to address the most pressing challenges is these disease research areas.

    Implementing NGS for the Study of Lymphoid Malignancies

    Gerard Frigola, MD

    Hematopathologist
    Hospital Clinic, IDIBAPS,
    University of Barcelona

    2024 AACR Poster

    AMP 2023 Workshop On-Demand: NGS for Myeloid Malignancy Analysis

    Cecilia Yeung, MD

    Professor, Translational Science and Therapeutics Division
    Medical Director, Fred Hutch Clinical Testing Labs
    Fred Hutchinson Cancer Center

    Cecilia Yeung

    Utility of NGS in Lymphoid Malignancies

    Dr. Michael Krigstein

    Consultant Haematologist
    MBBS(Hons) FRACP FRCPA MCncrSc
    SydPath, St Vincent’s Hospital

    Michael Krigstein

    The Time is Now for NGS-Based Clonality Testing

    Dr. Michael Hummel

    Charite

    Michael Hummel

    NGS for B Cell Receptor Sequencing in Multiple Myeloma

    Dr. Arthur Kowalik

    Holy Cross Cancer Center

    Arthur Kowalik

    Lymphoma Molecular Characterization - Assessing the Journey to Answers

    Dr. Marianne Grantham

    Barts Health NHS Trust

    Marianne Grantham

    Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasm

    Dr. John DeCoteau

    Professor of Pathology & Laboratory Medicine, Medical Director, Advanced Diagnostic Research Laboratory, University of Saskatchewan

    John DeCoteau

    How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms

    Dr. Bevan Tandon

    Director of Hematopathology
    and Molecular Pathology,
    Pathline Labs

    Bevan Tandon

    Molecular Analysis in the Diagnosis and Prognosis of Hematological Malignancies

    Dr. Geetha Menon

    Clinical Director
    HODS, Cheshire & Merseyside Cancer Network, Liverpool Clinical Laboratories.

    Geetha Menon

    Ready to speak to a Thermo Fisher representative?

    We will be happy to answer your questions and provide a demo of our NGS solutions.

    For Research Use Only. Not for use in diagnostic procedures.

    1x1 image pixel for data collection